<DOC>
	<DOCNO>NCT02901054</DOCNO>
	<brief_summary>Serotonergic 5-HT3 receptor central nervous system involve pain process nerve injury . We interested learn 5-HT3 receptor antagonist ondansetron might appropriate drug treat pain nerve injury ( neuropathic pain ) , investigate bio-distribution cerebro-spinal fluid , genetic variability may affect distribution . Study procedure include iv ondansetron administration , serial blood draw , cerebrospinal fluid ( CSF ) sampling , pregnancy testing , possible ECG .</brief_summary>
	<brief_title>CSF Pharmacokinetics Ondansetron</brief_title>
	<detailed_description />
	<mesh_term>Ondansetron</mesh_term>
	<criteria>1 . Age 18 70 year old ; 2 . Patients plan undergo hip knee arthroplasty spinal anesthesia ; 3 . Ability provide inform consent 1 . Not give consent participate study ; 2 . Patients history current hepatic renal insufficiency ; 3 . Patients BMI â‰¥ 33 ; 4 . Patients heart failure active arrhythmia ; 5 . Patients severe systemic disease constant threat life ; 6 . Contraindication allergy ondansetron ; 7 . Pregnancy lactation . 8 . Prisoners</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>